GeoVax Labs, Inc. (Nasdaq: GOVX) has announced the completion of key development milestones for its GEO-MVA vaccine candidate, which is being developed for mpox and smallpox. These milestones encompass manufacturing, regulatory, clinical, and preclinical aspects, and they set the stage for the initiation of a pivotal Phase 3 immune-bridging study expected to begin in the fourth quarter of 2026.
The company highlighted the completion of a comparative nonclinical immunogenicity study that evaluated GEO-MVA alongside the licensed MVA vaccine, Imvanex®. The study demonstrated that GEO-MVA generated robust orthopoxvirus-specific immune responses, as measured by both binding and neutralizing antibody assays. These findings bolster confidence in GEO-MVA's ability to elicit protective immunity comparable to the licensed vaccine, supporting the planned immune-bridging strategy.
Manufacturing readiness was a critical achievement: GeoVax has successfully manufactured, filled, packaged, and released GMP clinical product for use in the upcoming study. This milestone removes a significant barrier to clinical development and ensures that the trial can proceed without supply chain delays.
Regulatory alignment was also secured through engagement with the European Medicines Agency (EMA), whose Scientific Advice supports an expedited immune-bridging pathway. This pathway compares GEO-MVA with the licensed MVA-BN vaccine, potentially allowing for a more efficient route to licensure. The company's clinical operations are advancing with a contract research organization (CRO) engaged and clinical sites identified, targeting enrollment of 500 participants.
The preclinical immunogenicity data are particularly encouraging, as they show neutralizing antibody responses for GEO-MVA that are comparable to MVA-BN. These data are foundational to the immune-bridging design, which relies on demonstrating that GEO-MVA induces immune responses similar to those of the licensed vaccine.
Beyond clinical development, GeoVax is actively engaged in discussions with government agencies and international preparedness organizations regarding future procurement and long-term supply agreements. This commercial planning is a strategic move to position GEO-MVA as a key asset for biodefense and global health security.
David A. Dodd, Chairman and CEO of GeoVax, commented, "Completion of these milestones marks a significant inflection point for the GEO-MVA program as we prepare to initiate our pivotal immune-bridging study later this year. We have systematically executed the manufacturing, regulatory, clinical and scientific activities required to support successful study completion."
The company expects to initiate the Phase 3 study in Q4 2026 and report results in mid-2027. The study will compare immune responses generated by GEO-MVA with those of MVA-BN using established neutralizing antibody endpoints.
These developments come at a time when global health authorities are emphasizing the need for expanded orthopoxvirus vaccine supply. The completion of these milestones de-risks the GEO-MVA program and positions it for potential regulatory registration and commercialization, which could provide governments with an additional reliable source of MVA vaccine.
For more information, visit GeoVax's website or view the original press release on NewMediaWire.
